Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer a randomized open-label phase II study a randomized open-label phase II study

Journal of Thoracic Oncology

Volumn 9, Issue 11, 2014, Pages 1704-1708

  Natale, Ronald ^a   Blackhall, Fiona ^b   Kowalski, Dariusz ^c   Ramlau, Rodryg ^d   Bepler, Gerold ^e   Grossi, Francesco ^f   Lerchenmüller, Christian ^g   Pinder Schenck, Mary ^h   Mezger, Jörg ⁱ   Danson, Sarah ^j   Gadgeel, Shirish M ^e   Summers, Yvonne ^b   Callies, Sophie ^k   André, Valérie ^k   Das, Mayukh ^k   Lahn, Michael ^k   Talbot, Denis ^l  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e KARMANOS CANCER INSTITUTE   (United States)

^f UNIVERSITY OF GENOA   (Italy)

^g Onkologie und Palliativmedizin   (Germany)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ St Vincentius Kliniken GAG Med Klinik Abt 2   (Germany)

^j UNIVERSITY OF SHEFFIELD   (United Kingdom)

^k ELI LILLY AND COMPANY   (United States)

^l UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

Change in tumor size; Docetaxel; LY2181308; Non small cell lung cancer; Survivin

Indexed keywords

DOCETAXEL; GATAPARSEN; SURVIVIN; ANTINEOPLASTIC AGENT; OLIGONUCLEOTIDE; TAXOID;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; INVESTIGATIVE PROCEDURES; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; PATHOLOGY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDES; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84923138992     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000285     Document Type: Article

References (14)

1. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
3. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10.
4. Mita AC, Mita MM, Nawrocki ST, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14:5000-5005.
5. Carrasco RA, Stamm NB, Marcusson E, et al. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 2011;10:221-232.
6. Wiechno P, Somer BG, Mellado B, et al. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol 2014;65:516-520.
7. Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009;86:167-174.
8. Talbot DC, Ranson M, Davies J, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-inhuman dose study. Clin Cancer Res 2010;16:6150-6158.
9. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007;99:1455-1461.
10. Lavin PT. An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 1981;4:451-457.
11. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete oberservations. J Amer Statis Assn 1958;53:457-481.
13. Cox DR. Regression models and life-tables. J Royal Statis Soc, Series B (Methodological) 1972;34:187-220.
14. Ardizzoni A, Cafferata MA, Tiseo M, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006;107:2842-2849.